香港, 2024年8月14日 - (亞太商訊 via SeaPRwire.com) – 中國港能智慧能源集團有限公司（股份代號：0931.HK，以下簡稱「中國港能」）在香港成功召開2024年度業績投資者交流會。本次活動是自中國港能戰略轉型後首次面向全球投資者舉辦的線下交流會，不僅是中國港能在全球能源版圖中邁出堅實步伐的重要里程碑，更是一次面向未來、共謀綠色發展的深度對話。出席本次會議的有，中國港能董事會主席簡志堅，執行董事、總裁鄧耀波，副總裁劉永濤，陳雷昕，高級財務總監藍海。活動過程中，中國港能管理層就公司概况、財務表現及未來展望等內容與多家知名投資機構的投資者、分析師進行詳細介紹，並就行業發展和前景展開了深入交流，進一步加深資本市場對公司發展和前景的全面認知。新管理團隊加盟領航，業務轉型成效斐然為快速落實新的公司戰略，中國港能于2023年10月引進了一支擁有豐富管理經驗和市場洞察力的精英管理團隊，新的管理成員長期深耕于能源領域，具備成熟的行業管理經驗，能够穩定地駕馭複雜多變的行業環境。在過去的一年裡，公司原有天然氣存量業務穩步發展，同時在新的管理團隊帶領下，中國港能成功開拓了新能源業務，助推公司綠色能源戰略轉型，為公司長遠發展注入了新活力。財務指標增長强勢，多元化戰略未來可期截至2024年3月31日的財政年度內，在全新管理團隊的引領下，公司經營穩步發展，整體經營業績實現了令人矚目的114%年度同比增幅，毛利也取得了494%的大幅增長，彰顯出驚人的增長動能。在具體方面，中國港能原有天然氣業務持續穩健前行，相較去年同期實現了大幅增長，穩固了公司的業務基礎。同時公司在新能源領域取得了從零到一的飛躍性突破，構建起多元並進的收入增長格局。下半年度中國港能新佈局的新能源業務在短短四個月便迅速展現出强勁的市場適應性和盈利能力，進一步彰顯了公司在新能源領域的深厚潜力與市場競爭力。新能源+天然氣雙輪驅動，開啓智慧能源新篇章綠色能源轉型是歷史發展的必然趨勢，清潔能源市場前景充滿巨大想像空間，在新能源時代機遇之下，中國港能作為根植于傳統能源領域的企業，將緊緊抓住國家能源結構優化的政策機遇，持續緊跟市場趨勢，在保證天然氣業務基本盤穩定的前提下强化新能源業務拓展，在能源轉型歷程中實現社會與企業的雙贏。中國港能不僅將在能源轉型、管理升級上持續積極創新，同時也將繼續佈局人工智能、雙碳戰略、數字資產交易平台等新興領域，力求在全球能源舞台上發揮更加積極的作用，為股東持續創造更多價值。未來，中國港能將依托能源運輸和儲存的終端商業優勢，積極與國際夥伴開展合作，拓展業務輻射範圍，開拓上游市場版圖，不斷加强全球市場拓展和滲透，並通過天然氣和新能源業務積累的行業優勢，為可持續發展貢獻力量，為股東和合作夥伴創造長期價值。同時，中國港能也將積極響應國家號召，深入貫徹中共中央、國務院《關于加快經濟社會發展全面綠色轉型的意見》精神，將綠色發展理念融入企業發展戰略的核心，在《意見》明確指出的：構建綠色低碳高質量發展空間格局、加快產業結構綠色低碳轉型、穩妥推進能源綠色低碳轉型、推進交通運輸綠色轉型、推進城鄉建設發展綠色轉型等五大領域貢獻中國港能的智慧與力量，助力經濟社會全面邁向綠色化、低碳化發展。-完-關于中國港能中國港能智慧能源集團有限公司（簡稱「中國港能」），2001年在香港聯交所主板上市，股票代碼00931，主要經營新能源和天然氣業務的投資、建設、運營與技術服務的綜合能源服務商。中國港能致力于提供最優的能源系統方案，整合地熱能、空氣能、生物質能等多種清潔能源，依托自主研發的「IDH 智慧供熱」與「ICE 智慧綜合能源」技術平台，為居民小區、公共建築、工業企業等提供智慧綜合能源服務。公司還佈局了智慧供熱、綜合能效、裝備製造、雙碳等9大能源服務業務，推動現代能源體系建設。在天然氣領域，中國港能深耕產業鏈上下游，與多家油氣行業領軍企業建立長期合作關係，擁有近300台套自有LNG運輸車輛，構建了全國性的銷售網絡和供應鏈物流體系。同時，公司在城市管道燃氣、區域能源站等領域積極佈局，成為各地經濟社會和環保事業發展的重要力量。中國港能服務超過700個終端項目，業務遍及國內外20多個省市及澳大利亞、新西蘭、英國、德國等國家。公司榮獲多項榮譽，包括福佈斯亞洲區頂尖200最具成長型企業獎，並與國際能源署共同舉辦「能源可持續發展國際論壇」，被聯合國選為戰略合作夥伴。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年8月14日 - (亞太商訊 via SeaPRwire.com) – 靖洋集團控股有限公司（「靖洋集團」或「集團」，股份代號：8257.HK）宣佈截至 2024年6月30日止六個月（「期內」）之中期業績。期內，集團總收益約新台幣535.01百萬元。本公司擁有人應佔期間全面收益總額約新台幣31.30百萬元。每股基本盈利為新台幣3.87仙。期內，統包解決方案的收益約新台幣 226.60百萬元，佔集團總收益約42.35%。零件及二手半導體製造設備買賣的收益約新台幣308.41百萬元，佔集團總收益約57.65%。回顧期內，在地緣政治局勢持續緊張的環境下，本集團深化與現有國際客戶的合作關係，而且不斷探索新的合作領域和模式。本集團源自日本業務的收入較去年大幅增加7,038.01%，佔本集團總收益約9.79%，而源自美國業務的收入則較去年增加15.54%，佔本集團總收益約23.70%。在2024年上半年，生成式人工智能（AI）技術的興起為晶片及記憶體需求帶來了顯著的增長動力，然而，全球經濟環境的不確定性、工業和汽車市場的增速放緩等影響，使得整個半導體行業的復甦步伐不如預期。半導體產業協會(SIA)近日發表的數據顯示，2024年來全球半導體產業月度銷售額均實現同比增長。5月銷售額達491億美元，年度增長率高達19.3%，月度增長率也達到4.1%，年度增幅度是自2022年4月以來最大，充分展現生成式AI應用蓬勃發展態勢，為半導體產業帶來強大增長動力。靖洋集團主席兼行政總裁楊名翔先生總結：「隨著AI技術發展迅速，市場正邁入一個由AI全面賦能的新時代，這場變革不僅深度重構產業生態，更為半導體行業開啟了前所未有的黃金機遇。AI與高性能運算資料中心的強勁需求，驅動著晶片製造商與記憶體、封裝測試等企業之間建立起更為緊密的合作關係，攜手構建起一個強大的生態系統，從而增強整個產業鏈的綜合競爭力。然而，地緣政治的複雜態勢持續對全球半導體產業施加深遠影響，特别是AI作為中美科技競爭的核心領域。本集團將採取審慎的策略，靈活應對市場變化，緊抓發展機遇。同時，本集團也將致力於在關鍵技術上實現突破，以鞏固我們在激烈競爭中的市場地位，為股東創造長期、可持續的價值回報。」 關於靖洋集團控股有限公司（股份代號：8257.HK）靖洋集團控股有限公司為一間總部位於台灣的零件及二手半導體製造設備的統包解決方案供應商及出口商。集團自於2009年開始業務以來，主要為客戶提供零件二手半導體製造設備件的統包解決方案，按客戶需要改造及/或升級其生產系統的半導體設備，亦從事半導體製造設備及其零件買賣。集團所提供的半導體製造設備及零件包括熱爐管、顯影裝置等，用於半導體的前端製造過程、晶圓加工，如沉積、光阻塗佈及顯影，更可廣泛應用於手機、遊戲機、DVD播放機，以及車用感應器等數碼電子產品。本新聞稿由滙滔顧問有限公司代表靖洋集團控股有限公司發佈。詳情垂詢：劉育然小姐電話：(852) 2529 7999電郵：Natural.lau@vitalink.com.hk Copyright 2024 亞太商訊 via SeaPRwire.com.

The first ever copper-gold focused drilling program at the northern portion of the Nyngan Project will shortly commence with earn-in partner AngloGold Ashanti Australia (AngloGold Ashanti).New district-scale potential with up to eight large intrusive complex targets to be drill-tested for the first time in this initial first phase program.Approximately 6 to 8 drill holes for an estimated 4000-5000 metres budgeted before the summer break. Kincora is managing the program and will receive a 10% management fee. The program is the first by Kincora in partnership with AngloGold Ashanti, which has the right to spend up to A$50 million to earn an 80% interest in the Nyngan and Nevertire Projects.Fleet Space Technologies Pty Ltd's (Fleet Space) ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys at the Nyngan Project are progressing well and are expected to complement upcoming drilling.Melbourne, Australia--(ACN Newswire via SeaPRwire.com - August 14, 2024) - Kincora Copper Limited (TSXV: KCC) (ASX: KCC), (Kincora or the Company) is pleased to outline plans for the next chapter of copper-gold focused drilling in the Macquarie Arc, Central West New South Wales (NSW) with a first program in partnership with and funded by AngloGold Ashanti to shortly commence at the Nyngan Project.Sam Spring, President and CEO of Kincora, commented: "We are very excited by the potential of the Northern Junee-Narromine belt where we are seeking not to just confirm a new significant porphyry Cu-Au deposit but a new district and series of discoveries. The strategic appeal and value of a new porphyry district has been clearly illustrated in the Vicuña district with corporate activities by BHP and Lundin Mining this month supporting over C$8 billion of value being recognised for a cluster of four new major discoveries. Recent planning and targeting activities with our partner AngloGold Ashanti has significantly expanded the number of targets, the drilling activities needed and planned to test a series of major and previously undrilled interpreted magmatic complex targets at the Nyngan Project. Initially we are aiming to test up to eight new major intrusive system complex targets before year end in this first phase program which focuses on the very compelling northern Nyngan "Ace of Spades" region.Recent neighbouring explorer drilling is also supporting the potential of a series of Macquarie Arc intrusive complexes to the immediate east of the "Ace of Spades" target area along a potentially important common transverse structure providing further encouragement to the potential of a new porphyry district scale opportunity."BackgroundThe undercover extensions of the renowned Macquarie Arc porphyry copper-gold geology are globally significant exploration opportunities offering new district(s) scale discovery potential. The region has attracted four earn-in and joint venture agreements in the last 12 months supporting potentially over $200 million in exploration and development expenditure.The most recent notable example of a new emerging globally significant porphyry district is the Vicuña district in the central Andes in Argentina on the border of Chile, which is largely consolidated by Lundin group entities and BHP and situated at over 4000m altitude 1.Within this district NGEX Resources Inc in 2009 held three early-stage exploration projects and, at the time, had a market capitalisation of approximately C$40 million. These same projects are all still at a pre-development phase but have yielded four large-scale discoveries currently valued at over C$8 billion 2.In comparison, the central west of NSW benefits from multiple world-class mines, existing infrastructure, high-quality publicly available exploration data and an existing mineral endowment of over 160 million gold equivalent ounces 3. Regional geophysics strongly indicates that Kincora's Nyngan license hosts the largest volcano-intrusive complex of the Macquarie Arc, which is almost untested, offering new district scale potential.Kincora, as the early entrant, has secured a district scale position in the interpreted shallow-to-moderate covered core sections of the Northern Junee-Narromine Belt (NJNB) by pegging Nyngan and Nevertire which are now in partnership with AngloGold Ashanti 4.The imminent first-ever drilling program at the northern portion of the Nyngan Project will focus on the "Ace of Spades" region and test a wide range of untested, large intrusive-related Cu-Au targets. The program seeks to confirm the potential for a series of new Macquarie Arc intrusive complexes and provide vectors for follow up drilling - see Figure 1.Subject to permitting, access and weather conditions, the drilling program is anticipated to commence from mid September and will continue until the summer break, comprising up to eight holes for an estimated 4000-5000 metres.Recent planning and targeting activities with our partner AngloGold Ashanti have significantly expanded the number of targets, the drilling necessary to test a series of major and previously-undrilled interpreted magmatic complex targets at the Nyngan Project. This first program will test the potential for up to eight separate large intrusive complex targets.The program will comprise cost-effective mud-rotary drilling through the post mineral cover sequence with diamond core drilling upon refusal and testing of the targeted basement.Kincora is managing the exploration program and will receive a 10% management fee as the program is funded by AngloGold Ashanti via the up to $50 million earn-in and joint venture agreement for the Nyngan and Nevertire Projects.These drill targets include an existing high priority large intrusive complex target, which is currently the focus of Fleet Space's ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys within the northern portion of the Nyngan Project 5. Figure 1: District-scale series of major and untested magmatic complex targets with in the northern Nyngan "Ace of Spades" region that potentially represent the largest volcano-intrusive complex of the Macquarie Arc. Kincora is managing the exploration program and will receive a 10% management feeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/219846_kincora.jpgThe geophysical surveys are seeking to map and refine the interpretation of the paleo-surface and basement rocks and refine modeling of the targeted alteration, intrusions and structures.Recent neighbouring exploration drilling by Inflection Resources ("Inflection") is further supporting the potential of a series of Macquarie Arc intrusives to the immediate east of the "Ace of Spades" target area at Nyngan. Inflection has announced encouraging results at the Canonba target situated on the license boundary to the Nyngan Project, and located approximately 5km from its Duck Creek target, which is a Phase 2 designated project with its earn-in and joint venture partner AngloGold Ashanti 6. The Canonba, Duck Creek and Ace of Spades target areas potentially host important common transverse structures providing further encouragement about the potential of a new district-scale porphyry opportunity.About the Nyngan ProjectThe Nyngan license (Exploration Licence 8929) was the first ground Kincora secured in NSW. It is a large 762km2 direct application tenement granted by the NSW State Government covering a significant portion of the interpreted under cover section of the northern Junee-Narromine Belt 7. The Junee-Narromine Belt is one of the two largest belts of the Macquarie Arc, Australia's foremost porphyry belt, which hosts a mineral endowment of over 160 million gold equivalent ounces.The license hosts limited, but encouraging, prior explorer drilling that has been inadequately followed up, with regional geophysics supporting a new potential district-scale setting hosting interpreted, large-scale, intrusive complex targets.In May 2024, Kincora signed a definitive multiple-phase Earn-in and Joint Venture Agreement (Agreement) over the Nyngan and Nevertire licences with a wholly owned subsidiary of AngloGold Ashanti plc (NYSE: AU) (JSE: ANG), the world's fourth largest gold miner by production, which has a successful track record for Greenfields discovery success.AngloGold Ashanti has the right to spend up to A$50 million to earn an 80% interest through:A$25 million of exploration expenditure to earn a 70% joint venture interest (Phase I) including a minimum A$2 million expenditure obligation, with Kincora the initial operator for a 10% management fee. Completion of a Pre-Feasibility Study (PFS) or funding of a further $25 million of expenditure to earn a 80% joint venture interest (Phase II).In July 2024, separate to the Agreement with AngloGold Ashanti, Kincora formed a partnership with Fleet Space Technologies Pty Ltd (Fleet Space) to undertake Ambient Noise Tomography (ANT) and gravity geophysical surveys under a research and development grant at the Nyngan Project.Within the immediate district Fleet Space recently completed the world's largest ANT survey, undertaking a number of project-specific surveys that defined multiple new targets and built a proprietary AI-powered district-scale copper prospectivity map 8,9,10.The Fleet Space surveys are anticipated to complement Kincora and AngloGold Ashanti's planned exploration and upcoming drilling.About KincoraKincora Copper is dual listed on the ASX and TSX-V (ticker "KCC") and is an active explorer and project generator focused on world-class copper-gold discoveries. The company recently executed four agreements that unlock up to A$60 million in multiple year partner funding. Further new projects that offer a clear value path and targeted partnerships are proposed.Kincora's portfolio includes district scale landholdings and scalable drill-ready targets in both Australia and Mongolia's leading porphyry belts, the Macquarie Arc and Southern Gobi, respectively, and, the Company is targeting initial exposure to 10,000m of drilling in the next 6-month before ramping up to over 30,000 metres pa of drilling.For more information please visit Kincora's website at www.kincoracopper.comReferences:1 Lundin Mining and BHP to Acquire Filo and Form a 50/50 Joint Venture to Progress the Filo del Sol and Josemaria Projects - BHP and Lundin Mining press releases July 29, 20242 NGEX Minerals Corporate Presentation (July 2024) and market values as at July 29, 2024 (from peer transactions and TSXV market capitalization)3 Sourced from MinEx Consulting for Kincora4 AngloGold Ashanti to earn-in to the NJNB Project - Kincora press release May 28, 20245 ANT and Gravity Geophysical Surveys at the Nyngan Project - Kincora press release July 25th, 2024 6 Inflection Resources provides drilling update from Phase 1 Exploration Program in NSW - Inflection press release July 30th, 2024 7 Kincora secures strategic license in Australia's leading porphyry belt - Kincora press release November 21, 20198 ANT geophysics defines additional epithermal-porphyry targets at Spur Project - Waratah press release May 23, 20249 Reimaging porphyry copper exploration using Exosphere: Ambient Noise Tomography from the Duck Creek project, Macquarie Fleet and Inflection Case Study 2023 10 Completes 1,800Km2 Ambient Noise Tomography Survey Across Portfolio of Projects in New South Wales - Inflection press release July 10, 2024This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345Executive office 400 - 837 West Hastings Street Vancouver, BC V6C 3N6, Canada Tel: 1.604.283.1722 Fax: 1.888.241.5996Subsidiary office AustraliaVista AustraliaLevel 4, 100 Albert RoadSouth Melbourne, Victoria 3205Qualified PersonThe scientific and technical information in this announcement was prepared in accordance with the standards of the Canadian Institute of Mining, Metallurgy and Petroleum and National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and was reviewed, verified and compiled by Kincora's staff under the supervision of Peter Leaman (M.Sc. Mineral Exploration, FAusIMM), Senior Vice-President of Exploration of Kincora, and John Holliday (BSc Hons, BEc, member of the Australian Institute of Geoscientists), Non-Executive Director and Chairman of Kincora's Technical Committee, who are Qualified Persons for the purpose of NI 43-101.JORC Competent Person StatementInformation in this announcement that relates to Exploration Results, Mineral Resources or Ore Reserves are those that have been previously reported (with the original release referred to in this announcement), in the case of Mineral Resources or Ore Reserves the material assumptions and technical parameters underpinning the estimates have not materially changed, and have been reviewed and approved by Paul Cromie, who is a Competent Person under the definition established by JORC and has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaking to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'. John Holliday and Peter Leaman consents to the inclusion in this report of the matters based on his information in the form and context in which it appears. The review and verification process for the information disclosed herein for the Nyngan Projects have included the receipt of all material exploration data, results and sampling procedures of previous operators and review of such information by Kincora's geological staff using standard verification procedures.Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219846 Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection - Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your presence is the greatest protection for my love. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection - Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection - Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6022 1715Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Company is selected as a constituent to the MSCI Global Micro Cap Index (MSCI Hong Kong Micro Cap Index), with effect from the market close of 30 August 2024 (Friday).Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “We are confident that the Group's inclusion in the MSCI Hong Kong Micro Cap Index reflects the capital market’s appreciation of our business strategy and operational excellence. This development is anticipated to draw increased investor interest in the Group's growth prospects, potentially leading to a broader shareholder base. Looking ahead, we are actively enhancing our product portfolio and continuing to provide shareholders with greater value.”The MSCI Global Micro Cap Index captures micro cap representation across 23 developed markets countries. With 6,406 constituents, the index covers approximately 1% of the free float-adjusted market capitalization in each country. Assessments for the index are based on key factors, including minimum market capitalization, free float and liquidity, foreign inclusion factor requirement, and minimum length of trading requirement.- End -About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other Asian regions including Vietnam, Taiwan and Korea markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2024 ACN Newswire via SeaPRwire.com.

MELBOURNE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Mark your calendars for an unmissable event! We are thrilled to announce our partnership with the upcoming Modern DevOps Melbourne, taking place on October 8, 2024, at the prestigious Grand Hyatt Melbourne. This event promises to be a cornerstone for industry leaders and innovators in the DevOps community.Join us at Corinium's Modern DevOps Melbourne 2024, where you will have the opportunity to transform your DevOps delivery and explore revolutionary realms of platform engineering, DevSecOps, AI, and ModelOps. This is your chance to gain an unparalleled competitive edge in the ever-evolving tech landscape.We are extending a special invitation to all ACN Newswire via SeaPRwire.com readers, offering an exclusive discount code to join this invaluable industry gathering. Don't miss the chance to find inspiration, build new connections, and be part of a transformative experience.Get an exclusive $500 off the regular price by entering discount code DEVOPSPAR500 at checkout when registering.Keynote Speakers Include:Tim Baird, Senior Manager - DevOps, AIAMathangi VijayShankar, Engineering Lead API, MedibankAndrew Cunningham, Application Development & DevSecOps Team Lead, Australian Red Cross LifebloodJack Latrobe, Enterprise Architect – Sustainability External Relations & Legal, TelstraSerge Ambrose, Digital Technology Head – APAC, MMG LimitedAya Omar, Senior Manager Quality Engineering, WestpacParidhi Jha, Principal Machine Learning Engineer, Wesfarmers OneDigitalDave Lemphers, CTO, EasyGoNimisha Balyan, Chapter Lead, TelstraShivansh Sharma, Senior Manager Engineering - Platform & Reliability, TabcorpPouya Ghotbi, Security Lead APJ, AWSOlga Mirensky, Senior Platform Engineer, ANZNigel Fernandes, VP/GM Engineering (Ecosystem, Cloud, Platforms, Identity), XeroSean Duxbury, Principal Engineer – Google Cloud Platform, IAGDarragh Kennedy, Director of Engineering, ZendeskMichael Fornaro, Lead Cloud Engineer, ANZKey Themes at Modern DevOps Melbourne 2024:Maturing DevOps DNA: Elevate practices for greater efficiency and innovation in the software development lifecycle.Advance Your Toolchain with Automation, AI, and ML: Enhance scalability and efficiency in IT delivery.Bridging Legacy to Cloud: Unlock agility, scalability, and efficiency in modern DevOps practices.Unleash DevSecOps: Seamlessly integrate security measures into DevOps workflows.From Pipelines to Possibilities: Maximize the potential of CI/CD and deployment pipelines for DevOps velocity.This is an unparalleled opportunity to turbocharge scalable and secure DevOps deployment while aligning cyber and business strategies from a high-level perspective. Don't miss out on this chance to be part of Modern DevOps Melbourne!Register today: https://bit.ly/4ci5VsxAbout Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.For more information, please contact Moira Ungerleider at moira.ungerleider@coriniumgroup.com. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月13日 - (亞太商訊 via SeaPRwire.com) – 由香港貿易發展局 （香港貿發局） 主辦、文創產業發展處資助的亞洲時裝界年度盛事 CENTRESTAGE（香港國際時尚匯展），將於9月4至7日（星期三至星期六）假香港會議展覽中心隆重舉行，而開幕時裝騷CENTRESTAGE ELITES會於展會前一天（9月3日）假香港故宮文化博物館華麗上演。今屆CENTRESTAGE ELITES邀請到首位躋身巴黎高級訂製時裝周的香港時裝設計師 Robert Wun（雲惟駿）參與，他將以Home作為是次時裝騷主題。這將是Robert Wun 首次回歸香港的時裝騷，亦是香港故宮文化博物館首度上演時裝表演；觀眾將走過博物館標誌性的朱紅色大門進入會場，開展一段非凡的旅程。 Robert Wun 表示：「我的時裝設計師夢想在香港萌芽，這次回來香港舉辦時裝騷，令我過去十年的經歷、點滴、堅持和回憶都重新浮現出来。香港對我有著重要的影響，香港人的精神帶動我對工作充滿熱誠和魄力，我也承傳這裡的文化，擁有一顆感恩的心，飲水思源，適逢品牌十周年，我決定回來辦這個騷；而這場騷的設計和演繹，包含了一些我們（香港人）看得懂的元素。」他又預告：「我藉著新系列向嫲嫲致敬，設計靈感主要是來自香港女性不屈、勤勞的精神，及多才多藝的特點，還有我們文化上剛柔並重的感覺。我從香港的音樂、影視劇集及電影均得到不少啟發。」Robert Wun透露，在CENTRESTAGE ELITES中，除了會呈獻多套融入香港文化及情懷的嶄新設計之外，亦會重現他過去十年創作的經典作品，見證他圓滿回歸香港的重要時刻。展會分享大師心得Robert Wun於香港出生，2012年在倫敦時裝學院發表畢業設計系列時，被香港知名時裝集團Joyce Boutique發掘。他其後在2014年創立其同名品牌。Robert Wun的卓越成就得到各界認同，於2020年獲選為Fashion Asia Hong Kong* 10 Asian Designers To Watch之一；2022年榮獲 ANDAM Fashion Awards Prix Spécial 特別獎，並在2023年獲《Vogue Business 100》和《Tatler Asia》評選為時尚圈最具影響力人物之一。2023年1月，Robert Wun首次亮相巴黎時裝周，獲CHANEL總裁Bruno Pavlovsky大力支持，在時裝周的閉幕時裝騷發佈他的首個高級訂製服系列。Robert Wun的作品受到國際頂尖明星青睞，包括Beyoncé、Celine Dion、Lady Gaga、Adele、Cardi B、Florence Pugh 和 Billy Porter。此外，他亦曾為英國皇家芭蕾舞團、電影《飢餓遊戲》以及王家衛導演的電視廣告等設計服飾。（*文創產業發展處資助）Robert Wun成為國際頂尖時裝設計師的歷程極富啟發性，他將於CENTRESTAGE展會第二天（9月5日）主持大師分享會，分享其創作心得和心路歷程。與此同時，展會上亦會展出其別具匠心的設計。CENTRESTAGE是推廣環球設計師品牌及系列的亞洲時尚盛事，同時亦是區內時尚品牌發佈及推廣新系列和產品的理想平台。香港貿發局今年繼續邀請來自世界各地的業界人士到場參觀採購，並安排商貿配對活動，促進合作商機。一如過往，連場精彩活動，包括時裝表演、研討會、交流活動、時裝巡禮、香港青年時裝設計家創作表演賽等，將令與會者及觀眾收穫豐富、目不暇給。有關詳情將於8月20日於香港故宮文化博物館舉行的記者會公佈。圖片下載：https://bit.ly/3WP9hO2傳媒聯絡Best Crew Public Relations & Marketing鄧麗兒電話：(852) 9199 6723電郵：diana.tang@bestcrewpr.com郭穎軒電話：(852) 6291 4283電郵：reni.kwok@bestcrewpr.com香港貿發局傳訊及公共事務部：陳施樂 電話：(852) 2584 4537電郵：snowy.sn.chan@hktdc.org香港貿發局新聞中心︰http://mediaroom.hktdc.com/tc香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構，負責促進、協助和發展香港貿易。香港貿發局在世界各地設有50個辦事處，其中13個設於內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。請關注我們的 @香港貿發局 @香港貿發局時尚生活 @香港商貿通 香港貿發局 請訂閱香港貿發局文創產業發展處簡介文創產業發展處於2024年6月成立，前身為「創意香港」，是香港特別行政區政府文化體育及旅遊局轄下專責為文化和創意業界提供一站式服務與支援的辦公室，致力為香港營造有利的環境，促進藝術、文化及創意業界的產業化發展。現時的策略重點為培育人才及促進初創企業的發展、開拓市場、推動更多跨界別、跨文化藝術領域的合作、推動文化藝術和創意業界產業化發展，以及推動香港成為亞洲創意之都，並在社會營造創意氛圍，以落實國家《十四五規劃綱要》下香港作為中外文化藝術交流中心的定位。網址：https://www.ccidahk.gov.hk。Fashion Hong Kong 簡介Fashion Hong Kong 是香港貿易發展局（香港貿發局）推廣香港時裝設計的活動，銳意帶領香港時裝設計師及品牌連繫國際市場。香港貿發局將於 9月3日CENTRESTAGE ELITES時裝表演當天，在香港故宮文化博物館地下展出10位今屆Fashion Hong Kong設計師的作品，並會於9月4日在香港會議展覽中心舉辦Fashion Hong Kong Runway Show。 Fashion Hong Kong Runway Show 由香港貿發局主辦、文創產業發展處資助，將由導演陳志發執導，以電影手法呈獻四個香港時裝品牌ANGUS TSUI、röyksopp gakkai、selfFab.、Z I D I 的全新2025 春夏系列作品。展會網頁CENTRESTAGE 展會網頁：www.centrestage.com.hkCENTRESTAGE ELITES網頁：http://www.hktdc.com/event/centrestage/tc/centrestage-elitesFashion Hong Kong 網頁：https://www.fashionhongkong.com.hk/tc香港青年時裝設計家創作表演賽(YDC)網頁：www.fashionally.com/zh-hk/免責聲明：香港特別行政區政府僅為本項目提供資助，除此之外並無參與項目。在本刊物／活動內（或由項目小組成員）表達的任何意見、研究成果、結論或建議，均不代表香港特別行政區政府、文化體育及旅遊局、文創產業發展處、「創意智優計劃」秘書處或「創意智優計劃」審核委員會的觀點。 Copyright 2024 亞太商訊 via SeaPRwire.com.

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection - Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your gentleness is my greatest safeguard in this life. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection - Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection - Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6992 2589Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

Development Highlights- During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs.- In the first half of 2024, the Group's revenue from innovative products reached RMB 6.13 billion, a year-on-year increase of 14.8%. In addition to innovative products, the Group has 11 generic drugs approved by the NMPA for market launch. The overall revenue of generic drugs achieved positive growth in the first half of 2024. New products are an important driver of the Group’s revenue growth. In the first half of 2024, the Group’s revenue from new products launched within five years reached RMB 6.03 billion, representing a year-on-year increase of 39.6%.- As of 30 June 2024, the Group had a total of 43 innovative drug candidates in the field of oncology, 8 innovative drug candidates related to the respiratory system, 6 innovative drug candidates related to liver disease, and 4 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 3 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 5 innovative oncology drug candidates, 1 innovative respiratory system drug candidate, 1 innovative liver disease drug candidate, and 1 innovative surgery/analgesia drug candidates are in Phase III clinical trials. In addition, the Group had a total of 18 biosimilar or generic drug oncology candidates, 3 additional biosimilar or generic liver disease drug candidates, 21 biosimilar or generic respiratory system drug candidates, and 10 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. In February and July 2024, for anlotinib in combination with benmelstobart, two marketing applications were submitted to the Center for Drug Evaluation (“CDE”) of NMPA for the treatment of second- and third-line endometrial cancer, and first line renal cell carcinoma, respectively. In July 2024, the Phase III clinical study of anlotinib in combination with chemotherapy for the first-line treatment of advanced soft tissue sarcoma achieved positive results. The Group has submitted the marketing application and received acceptance for the new indication.- Yilishu (Efbemalenograstim Alfa Injection) was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs. In December 2023, Efbemalenograstim alfa was successfully included in the National Reimbursement Drug List (“NRDL”), and its sales volume accelerated in the first half of 2024, becoming an important contributor to the Group’s revenue growth.- Andewei (Benmelstobart Injection) is a humanized PD-L1 monoclonal antibody that was approved by the NMPA in April 2024 for use in combination with anlotinib, carboplatin, and etoposide in the first-line treatment of extensive-stage small cell lung cancer.- Anboni (Unecritinib Fumarate Capsules) is a small molecule inhibitor of tyrosine kinase ROS1/ALK/c-Met, which was approved by the NMPA in April 2024 for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer. It is the first domestically produced targeted drug approved for the treatment of ROS1-positive non-small cell lung cancer.- The clinical trial application of Lanifibranor was submitted to and accepted by CDE in March 2023. In July, Lanifibranor was included in the list of breakthrough therapeutics. Currently, Lanifibranor is conducting Phase III clinical trials globally and is actively advancing the enrollment of subjects. Lanifibranor is China's first oral MASH drug to enter Phase III clinical trials and is expected to fill the gap in China's MASH market.HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the “Period”).During the Period, the Group recorded revenue of approximately RMB15.87 billion, a year-on-year increase of approximately 11.1%. Profit attributable to owners of the parent company was approximately RMB3.02 billion, a year-on-year increase of approximately 139.7%. Earnings per share attributable to owners of the parent company were approximately RMB16.39 cents. The significant year-over-year increase in profit attributable to owners of the parent company was mainly due to the gain on disposal of subsidiaries under discontinued operations during the current Period. Adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB1.54 billion, a YOY increase of approximately 14.0%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB8.55 billion, bank deposits classified as non-current assets of approximately RMB9.18 billion, and wealth management products of approximately RMB4.61 billion in total, and total fund reserves amounting to approximately RMB22.34 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK3 cents per share (1H2023: HK2 cents).Miss Tse, Theresa Y Y, Executive Director and ChairwomanSales: Entering harvesting of innovative results period and sales revenue from generic products further risesAlways placing utmost importance on research and development (“R&D”), the Group leverages in-depth research and development to achieve significant benefits. At present, the Group has entered the harvest period of its innovative development, driving further growth in sales revenue. During the Period, sales of oncology drugs increased by 19.5% year-on-year to approximately RMB5.36 billion, accounting for approximately 33.8% of the Group's revenue. Sales of surgical/analgesic medications increased by 29.9% year-on-year to approximately RMB2.58 billion, accounting for approximately 16.3% of the Group's revenue. Sales of liver disease drugs amounted to approximately RMB2.03 billion, accounting for approximately 12.8% of the Group's revenue. In addition, the sales contributions of products in various areas such as respiratory system, cardio-cerebral vascular medicines, and others increased simultaneously, accounting for approximately 11.2%, 8.6%, and 17.3% of the Group's total revenue, respectively.In the field of respiratory system, The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the volume-based procurement (VBP), enabling Tianqing Suchang’s sales to achieve steady growth during the Period. In the meanwhile, the Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly during the Period.In the field of surgery/analgesia, the Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth during the Period.Mr. Tse, Eric S Y, Executive Director and Chief Executive OfficerR&D: R&D as the core for driving the Group's continuous innovation and developmentThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver disease, respiratory system and surgery/analgesia. As at the end of the reporting Period, the Group had 76 innovative products in development, including 46 oncology products, 6 liver disease products, 9 respiratory system products, 5 surgery/analgesia products, and 10 other products. In addition, the Group had 65 generic drug products in development.The Group has always put R&D at its core, and has continuously improved its R&D capabilities and speed by embracing the R&D concept of combining independent innovation, collaborative development, and the development of both innovative and generic drugs. It considers R&D as the foundation of its sustainable development. In the first half of 2024, it incurred R&D expenses of approximately RMB 2.58 billion, accounting for approximately 16.2% of the Group’s revenue. It is expected that the number of innovative products launched to the market will reach 25 by 2026. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for long-term sustainable growth.Sino Biopharmaceutical ManagementProspects: Keep up with national development strategy and accelerate globalization processThe pharmaceutical industry has become one of the fastest growing and most promising fields in China and even the world. As the world’s second largest pharmaceutical market, China’s demand for medical and healthcare products has grown rapidly in recent years, with breakthroughs being made in biotechnology. Innovation has become a new driving force for the high-quality development of China’s pharmaceutical industry. The Group has been closely monitoring the development of the country, society and the industry, and has continuously optimized its development strategy. Under the four main strategies of “organizational integration, comprehensive innovation, internationalization, and digitalization”, the Group will actively innovate its organizational structure, comprehensively improve its operational efficiency, focus on the innovation and development of the four main therapeutic areas of oncology, liver disease, respiratory system, and surgery/analgesia, and actively accelerate the global deployment of its business.The Group is committed to its mission of becoming a “leading global pharmaceutical company through delivering innovative therapies for patients”. It strives to promote innovative development through its dual engines of internal R&D and business development. Over the years, the Group has stepped up its R&D investment and built strong internal R&D capabilities. At the same time, it has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises. In April 2024, the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the Mainland Chinese market. This move not only demonstrates The Group's innovative strength in the pharmaceutical field, but also reflects its far-reaching influence in international cooperation.Looking ahead, The Group will adhere to its dual-pronged approach in the implementation of its globalization strategy. Through this approach, the Group will bring global pharmaceutical innovations to China to benefit Chinese patients, and also go global and open up new markets to accelerate the satisfaction of unmet clinical needs worldwide. Copyright 2024 ACN Newswire via SeaPRwire.com.

重點成果- 期內，集團共有4個創新產品獲中國國家藥品監督管理局（「NMPA」）批准上市，分別為安得衛（貝莫蘇拜單抗注射液）、安柏尼（富馬酸安奈克替尼膠囊）、安洛晴（枸櫞酸依奉阿克膠囊）和貝樂林（利拉魯肽注射液），其中3個為國家1類創新藥。- 2024年上半年，集團創新產品收入達到61.3億元，同比增長14.8%。除創新產品外，集團還有11個仿製藥獲NMPA批准上市，整體仿製藥收入在2024年上半年已實現正增長。新產品是驅動集團收入增長的重要動力，2024年上半年集團5年內上市的新產品收入達到60.3億元，同比增長39.6%。- 截至2024年6月30日，集團共有43個腫瘤領域、8個呼吸系統領域、6個肝病領域和4個外科╱鎮痛領域的創新候選藥物處於臨床申請及以上開發階段。其中，3個腫瘤領域、1個外科╱鎮痛領域產品處在上市申請階段；5個腫瘤領域、1個呼吸系統領域、1個肝病領域、1個外科╱鎮痛領域的創新候選藥物處於臨床III期；另有18個腫瘤領域、3個肝病領域、21個呼吸系統領域、10個外科╱鎮痛領域的生物類似藥或仿製藥候選藥物處於臨床申請及以上開發階段。- 福可維（鹽酸安羅替尼膠囊）是一種新型小分子多靶點酪氨酸激酶抑制劑。2024年2月和7月，安羅替尼聯合貝莫蘇拜單抗向中國國家藥品監督管理局藥品審評中心（「CDE」）遞交兩項新適應症上市申請，分別用於治療二三線子宮內膜癌和一線腎細胞癌。2024年7月，安羅替尼聯合化療用於晚期軟組織肉瘤一線治療的III期臨床研究取得陽性結果，集團已遞交新適應症上市申請並獲受理。- 億立舒（艾貝格司亭α）注射液於2023年5月獲批用於預防和治療腫瘤患者在接受化療藥物後出現的中性粒細胞減少症。2023年12月，億立舒被成功納入國家醫保目錄，並在2024年上半年加速放量，成為集團收入增長的重要貢獻品種。- 安得衛（貝莫蘇拜單抗注射液）是一款人源化PD-L1單克隆抗體，於2024年4月獲得NMPA的上市批准，用於聯合安羅替尼、卡鉑和依託泊甘一線治療廣泛期小細胞肺癌。- 安柏尼（富馬酸安奈克替尼膠囊）是一款酪氨酸激酶ROS1/ALK/c-Met小分子抑制劑，於2024年4月獲得NMPA的上市批准，用於治療ROS1陽性的局部晚期或轉移性非小細胞肺癌，是首個獲批用於治療ROS1陽性非小細胞肺癌的國產靶向藥。- 拉尼蘭諾（泛PPAR激動劑）於2023年3月向CDE遞交臨床試驗申請並獲得受理，7月，拉尼蘭諾被CDE納入突破性治療品種名單。目前該產品正在全球進行III期臨床試驗，是中國第一個進入臨床III期的MASH口服藥物，有望填補中國MASH市場空白。香港, 2024年8月14日 - (亞太商訊 via SeaPRwire.com) – 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2024年6月30日止6個月（「期內」）之未經審核財務業績。回顧期內，集團收入同比增長11.1%至約158.7億元（人民幣，下同）。歸屬於母公司持有者應佔盈利約30.2億元，同比增長約139.7%，基於歸屬於母公司持有者應佔盈利計算之每股盈利約16.39分。歸屬於母公司持有者盈利同比顯著增加主要由於本期間錄得處置附屬公司收益並計入已終止經營業務導致。經調整非《香港財務報吿準則》歸母淨利潤約15.4億元，同比增長約14.0%。集團流動資金保持充裕，期內有計入流動資產之現金及銀行結餘約85.5億元、計入非流動資產之銀行存款約91.8億元，理財管理產品總額約46.1億元，資金儲備合共約223.4億元。董事會建議派發中期股息每股3港仙（2023上半年：2港仙）。中國生物製藥董事會主席謝其潤女士銷售：邁入創新成果收穫期 創新產品銷售收入持續增加集團一直以來重視研發，並憑藉高研發投入以獲得顯著收益。集團現已步入創新成果密集收穫期，帶動銷售收入進一步增長。期內，抗腫瘤用藥之收入同比增加19.5%，達約53.6億元，佔集團收入約33.8%。外科／鎮痛用藥之收入同比增加29.9%，達約25.8億元，佔集團收入約16.3%。肝病用藥收入錄得約20.3億元，佔集團收入12.8%。此外，呼吸系統、心腦血管用藥和其他等不同領域產品的銷售貢獻多輪並進，分別佔集團收入約11.2%、8.6%和17.3%。於呼吸系統領域，集團及時採取了一系列主動管理措施，包括管道下沉、拓展市場覆蓋和集採外市場的二次開發，使天晴速暢銷售額於期內實現了穩步增長。同時，集團通過積極的學術推廣，不斷拓展市場覆蓋，令天韻的銷售額於期內亦取得快速增長。於外科╱鎮痛領域，集團聚焦高潛地區開發，深入拓展市場覆蓋，並逐步擴大產能，以滿足市場的旺盛需求。氟比洛芬凝膠貼膏的銷售額在過去幾年保持增長態勢，並在期內實現了突破性增長。中國生物製藥董事會首席執行長謝承潤先生研發：以研發為核心，驅動集團持續創新與發展集團繼續專注腫瘤、肝病、呼吸系統和外科╱鎮痛四大治療領域的新產品研發。截至報告期日，集團有在研創新產品76個，其中腫瘤用藥46個、肝病用藥6個、呼吸系統用藥9個、外科╱鎮痛用藥5個，其他類用藥10個。另外，集團還有65個在研仿製藥產品。集團始終將研發置於核心位置，秉承自主創新、聯合開發及創仿開發相結合的研發策略，持續提高研發能力和效率，將其視為企業持續發展的關鍵。2024年上半年集團研發費用達到約25.8億元，佔集團收入約16.2%。預計到2026年，已上市創新産品的數量將達到25個，將進一步強化集團在四大治療領域的優勢地位，爲長期可持續增長注入強大動力。中國生物製藥管理層展望：緊跟國家發展戰略，加速國際化進程醫藥行業已成為中國乃至全球最具活力和發展潛力的領域之一。中國作為全球第二大醫藥市場，近年來醫療健康需求的快速增長和生物技術的持續突破，為醫藥產業的高質量發展注入了新動力。集團緊跟國家、社會及行業的最新動態，不斷優化發展策略，以「組織整合、全面創新、國際化、數字化」為四大戰略方向，積極革新組織架構，全面提升運營效率，專注於腫瘤、肝病、呼吸、外科/鎮痛四大治療領域的創新發展，並大力推進國際化佈局。集團秉承「專注創新、服務病患，成為全球領先的製藥企業」的願景，通過自主研發和商務拓展的雙引擎驅動，不斷推動創新發展。集團不斷加大研發投入，積累了強大的自主研發能力。同時，集團積極推進商務拓展和戰略合作，力爭成為全球製藥與生物科技公司的的最佳合作夥伴。2024年4月，集團與勃林格殷格翰建立戰略合作夥伴關係，將勃林格殷格翰的創新抗腫瘤療法引入中國大陸市場，這一舉措不僅展現了集團在醫藥領域的創新實力，也體現了其在國際合作中的深遠影響力。展望未來，集團將持續堅守「引進來」與「走出去」的雙重策略，以實現國際化發展。集團將全球的醫藥創新成果引入中國，為中國的病患帶來福祉；同時也將積極開拓新的市場，以加速滿足全球各地未被滿足的臨床需求。 Copyright 2024 亞太商訊 via SeaPRwire.com.